Alzheimers News

Stem Cell Therapeutics Corp. Announces Fiscal 2005 Year End Financial Results
    TSX-Venture Exchange: SSS     CALGARY, March 22 /PRNewswire-FirstCall/ - Stem Cell Therapeutics Corp. ("SCT") today announced its financial results for the period ended December 31, 2005.     Selected Highlights     During the fiscal period ended December 31, 2005, SCT achieved ...

Fifteen Nonprofits Complete New Charities Review Council Accountability Wizard Process
    SAINT PAUL, Minn., March 23 -Fifteen charitable organizations have already completed the new Charities Review Council of Minnesota (the Council) review process, known as the Accountability Wizard. All of the nonprofits met the Council's established standards in four critical areas: Public Disclosure, Governance, Financial Activity and ...

Pfizer to Expand Neuroscience Research With Acquisition of Biotech Company Rinat Neuroscience
Rinat Portfolio Includes Early Research in Alzheimer's disease, Phase II     Candidate in Acute and Chronic Pain     NEW YORK, and SOUTH SAN FRANCISCO, Calif., April 6 /PRNewswire-FirstCall/ -- Pfizer Inc announced today it has entered into an agreement to acquire Rinat Neuroscience Corp., a privately held ...

Forest Laboratories, Inc. Reports Q4'06 Diluted Earnings Per Share of $0.28 Including $0.37 Per Share Charge for Licensing and Milestone Payments
     Company Provides FY'07 Earnings Per Share Guidance     NEW YORK, April 25 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today reported financial results for its fiscal fourth quarter ended March 31, 2006.    (Logo: ...

Role of Cholesterol in Alzheimers Disease Unclear, Reports the Harvard Mens Health Watch
BOSTON, Feb. 23 /-USNewswire/ -- It sounds simple: The lower your cholesterol, the better your heart health. But a man's heart and his head don't always agree. In fact, the relationships among cholesterol levels, psychological function, and neurologic disorders are complex and sometimes controversial, reports the March 2007 issue of Harvard Men's Health ...

Memory Pharmaceuticals Reports Phase 2a Results for MEM 1003 in Bipolar Disorder
Company to Host Conference Call at 9:00 a.m. to Discuss Results     MONTVALE, N.J., March 5 Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced top-line data from the Phase 2a study of MEM 1003 in acute mania in bipolar disorder, which was conducted with funding support from the Stanley Medical Research Institute. An analysis of the ...

Alzheimers Disease Prevalence Rates Rise to More Than Five Million in the United States
- Someone Develops Alzheimer's Every 72 Seconds, According To New     Alzheimer's Association Report -     WASHINGTON, March 20 /-USNewswire/ -- The Alzheimer's Association today reports that in 2007 there are now more than 5 million people in the United States living with Alzheimer's disease. This ...

Avicena Announces Patient Enrollment in National Institutes of Health (NIH) Phase III Parkinsons Disease Trial
5-year Study to Enroll More Than 1,700 patients at Over 50 Sites in US and     Canada     One of Largest Parkinson's Disease Trials Ever Conducted     PALO ALTO, Calif., March 22 Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company focused on ...

Alzheimers Growth Shows Need for Increased FDA Funding
Coalition for a Stronger FDA says drug review programs need more money     WASHINGTON, March 21 /-USNewswire/ -- A new estimate by the Alzheimer's Association shows that more than five million Americans are living with Alzheimer's disease -- a 10 percent growth over previous estimates and a number that could more than triple in the coming ...

Transition Therapeutics Inc. Builds on Its CNS Franchise with the Acquisition of NeuroMedix Inc.
TORONTO, March 21 - - Transition Therapeutics Inc. ("Transition") (TSX: TTH) announced today that it has signed an agreement to offer to purchase all of the outstanding shares of NeuroMedix Inc. ("NeuroMedix"), a central nervous system ("CNS") focused biopharmaceutical company. NeuroMedix is developing a series of compounds that have been shown to improve ...

NeuroMedix receives acquisiton offer by Transition Therapeutics
TORONTO, March 21 - - NeuroMedix Inc. ("NeuroMedix") (TSXV: NMX) today announced that is has agreed to support a tender offer made by Transition Therapeutics Inc. ("Transition") to acquire all of the outstanding shares of NeuroMedix. "This deal with Transition represents good value for our shareholders", said Dr. Mark L. Pearson, Chief Executive ...

Sanarus Medical, Inc. Appoints John F. Howe as President and Chief Executive Officer
PLEASANTON, Calif., March 22 // -- Sanarus Medical, Inc., a leading developer of minimally invasive medical devices for diagnosing and treating breast disease, announced today that John F. Howe has been promoted to the position of President and Chief Executive Officer. Mr. Howe has been the Chief Operating and Chief Financial Officer for the company since November ...

Amorfix provides corporate update on therapeutics program for Amyotrophic Lateral Sclerosis (ALS or Lou Gehrigs disease)
/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TSX Venture: AMF TORONTO, March 23 - - Amorfix Life Sciences Ltd. (TSX-V:AMF), a theranostics company developing diagnostics and treatments for aggregated misfolded protein (AMP) related diseases, today announced Dr. Neil ...

Avicena Clarifies Description of Creatine Versus PD-02, Companys Lead Drug Compound Used in NIH Phase III Clinical Trial in Parkinsons Disease
PALO ALTO, Calif., March 23 Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company focused on commercializing its proprietary cellular energy modulation technology, wishes to clarify the difference between its compound, PD-02, being used in the Phase III Parkinson's disease trial announced on March 22, 2007, versus a common (nutritional ...

Michael J Fox Statement on Passage by the U.S. Senate of Stem Cell Research Enhancement Act (S. 5)
WASHINGTON, April 11 /-USNewswire/ -- I am pleased to join millions of Americans in thanking Senate Majority Leader Harry Reid and Senators on both sides of the aisle for putting partisan differences aside and passing S. 5, the Stem Cell Research Enhancement Act. It's a great day for scientists and patients across this country.    This vote ...

Coley Pharmaceutical Group Licenses VaxImmune(TM) to Merck for Use in Vaccine Programs
WELLESLEY, Mass., April 12 Coley Pharmaceutical Group, Inc. (Nasdaq: COLY) today announced that Merck & Co., Inc. has licensed Coley's VaxImmune(TM) vaccine adjuvant for incorporation into vaccines being developed by Merck for certain infectious diseases and Alzheimer's disease.    Under the terms of the agreement, Merck has agreed to pay Coley ...

Ceregene Enrolling Patients for Phase 2 Clinical Trial of Parkinsons Disease
Phase 1 Data Showed Reduction in Parkinson's Disease Symptoms of Nearly 40     Percent     SAN DIEGO, Calif., April 13 // -- Ceregene, Inc., a biopharmaceutical company, confirmed today that enrollment is well under way in its randomized, controlled, double-blind, Phase 2 clinical trial evaluating ...

lexdon


2001 - 2015 Lexdon Business Library
TrustBase Registration
Privacy Policy
eTrust Privacy Certified